Disease
Psoriasis
Chronic, immune-mediated inflammatory skin disease driven by IL-23/Th17-axis dysregulation, presenting as well-demarcated erythematous plaques with silvery scale; the most common presentation is chronic plaque psoriasis, though pustular and erythrodermic subtypes also occur.
Total attributable cost
$87.4B
$11,062/patient
Drug spend
Not yet sourced
All severities, physician-diagnosed history (2023 NHIS) · US